The FDA approved the MEK inhibitor cobimetinib in combination with vemurafenib (a BRAF inhibitor) for the treatment of patients with mutant BRAF V600E metastatic melanoma after a phase III controlled randomized trial comparison study between vemurafenib alone and vemurafenib and cobimetinib in combination. Here, BRAF is linked to metastatic melanoma.